Oramed Pharmaceuticals Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 3/6

Oramed Pharmaceuticals hat ein Gesamteigenkapital von $165.7M und eine Gesamtverschuldung von $32.0M, was einen Verschuldungsgrad von 19.3% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen $203.7M bzw. $37.9M.

Wichtige Informationen

19.3%

Verhältnis von Schulden zu Eigenkapital

US$32.03m

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	US$176.59m
Eigenkapital	US$165.72m
Gesamtverbindlichkeiten	US$37.93m
Gesamtvermögen	US$203.65m

Jüngste Berichte zur Finanzlage

Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation

Aug 24

Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans

May 03

Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth

Dec 22

Is Oramed Pharmaceuticals (NASDAQ:ORMP) In A Good Position To Invest In Growth?

Jun 12

Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth

Feb 23

Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation

Nov 02

Recent updates

Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation

Aug 24

Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans

May 03

Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth

Dec 22

Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth

Feb 23

Oramed And The Hurdles Of Developing Oral Insulin

Dec 23

Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation

Nov 02

Oramed: Prospects Still Remain Despite Merck-Ridgeback's Progress

Oct 04

We Think Shareholders Will Probably Be Generous With Oramed Pharmaceuticals Inc.'s (NASDAQ:ORMP) CEO Compensation

Aug 24

Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans

Jul 21

Oramed reaches 50% enrollment in late-stage oral insulin study

Jun 08

Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans

Apr 06

The Oramed Pharmaceuticals (NASDAQ:ORMP) Share Price Is Up 110% And Shareholders Are Boasting About It

Feb 12

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: ORMPDie kurzfristigen Aktiva des Unternehmens ($177.1M) übersteigen seine kurzfristigen Passiva ($33.6M).

Langfristige Verbindlichkeiten: ORMPDie kurzfristigen Vermögenswerte des Unternehmens ($177.1M) übersteigen seine langfristigen Verbindlichkeiten ($4.4M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: ORMP über mehr Barmittel verfügt als seine Gesamtverschuldung.

Schulden abbauen: ORMPDas Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 0% auf 19.3% gestiegen.

Schuldendeckung: ORMPDer operative Cashflow des Unternehmens ist negativ, so dass die Schulden nicht ausreichend gedeckt sind.

Zinsdeckung: Unzureichende Daten, um zu bestimmen, ob die Zinszahlungen von ORMP für seine Schulden durch das EBIT gut gedeckt sind.

Oramed Pharmaceuticals Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 3/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation

Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans

Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth

Is Oramed Pharmaceuticals (NASDAQ:ORMP) In A Good Position To Invest In Growth?

Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth

Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation

Recent updates

Oramed Pharmaceuticals Inc. Appoints Mr. Avraham Gabay as Treasurer and Secretary, Effective as of June 18, 2024

Consensus revenue estimates decrease by 50%

Consensus revenue estimates increase by 15%

New major risk - Revenue and earnings growth

First quarter 2024 earnings released: EPS: US$0.038 (vs US$0.085 loss in 1Q 2023)

New minor risk - Market cap size

Oramed Pharmaceuticals Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Full year 2023 earnings: EPS and revenues exceed analyst expectations

New minor risk - Share price stability

Consensus EPS estimates fall by 50%

Insufficient new directors

Oramed Pharmaceuticals Inc. Appoints Daniel Aghion as Director, Effective January 1, 2024

Third quarter 2023 earnings released: US$0.08 loss per share (vs US$0.18 loss in 3Q 2022)

New minor risk - Market cap size

Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation

Consensus EPS estimates upgraded to US$0.34 loss

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Oramed Pharmaceuticals Inc. (NasdaqCM:ORMP) entered into a Stalking Horse Stock Purchase Term Sheet to acquire a 40.17% stake in Scilex Holding Company (NasdaqCM:SCLX) from Sorrento Therapeutics, Inc. (OTCPK:SRNE.Q) for approximately $110 million.

Oramed Pharmaceuticals Inc., Annual General Meeting, Jul 13, 2023

Oramed Pharmaceuticals Inc., Annual General Meeting, Jul 13, 2023

Consensus EPS estimates fall by 13%

Consensus EPS estimates upgraded to US$0.35 loss

Price target decreased by 82% to US$2.40

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans

President recently bought US$201k worth of stock

Independent Director recently bought US$142k worth of stock

Consensus EPS estimates upgraded to US$0.59 loss

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased by 23% to US$15.16

Price target decreased to US$21.67

Oramed Pharmaceuticals Inc. Announces Top-Line Results from Phase 3 Trial of ORMD-0801 for the Treatment of Type 2 Diabetes

Oramed Pharmaceuticals Inc. Granted U.S. Combination Therapy Patent for Oral Glp-1 & Insulin for the Treatment of Diabetes

Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth

Price target decreased to US$28.67

Oramed Announces Additional Positive Safety and Efficacy Data from Its Phase 2 Clinical Trial of ORMD-0801 for NASH

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

High number of new and inexperienced directors

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Oramed: Oral Insulin For Type 2 Diabetes May Become A Reality

Oramed Pharmaceuticals Inc. Reports Positive Top-Line Results from Phase 2 Nash Trial with its ORMD-0801, Oral Insulin Candidate

Oramed to hand Korean rights for insulin capsule

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Oramed Reaches 50% Enrollment in Its Second Phase 3 Oral Insulin Trial

High number of new and inexperienced directors

Oramed to report early-stage trial data for oral COVID-19 shot in 3Q

Is Oramed Pharmaceuticals (NASDAQ:ORMP) In A Good Position To Invest In Growth?

Oramed Pharmaceuticals Inc., Annual General Meeting, Jun 30, 2022

Oramed Pharmaceuticals Inc. Appoints Anne Peters to Its Scientific Advisory Board

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Oramed Pharmaceuticals Inc. Completes Patient Enrollment in Pivotal Phase 3 Oral Insulin Study Ora-D-013-1

Price target increased to US$32.50

Oramed And Oral Insulin: Can This Small Company Really Do It?

Oramed Pharmaceuticals Inc. Grants NASH Patent in Europe

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Independent Chairman of the Board recently sold US$94k worth of stock

Consensus forecasts updated

Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus forecasts updated

Oramed And The Hurdles Of Developing Oral Insulin

Oramed Subsidiary Oravax Announces First Participant Enrolled in Phase 1 Oral Covid-19 Vaccine Trial in South Africa

Full year 2021 earnings: EPS and revenues miss analyst expectations

Oramed Pharmaceuticals Inc. Reaches 75% Enrollment in Phase 3 Oral Insulin Study

Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation

Oramed: Prospects Still Remain Despite Merck-Ridgeback's Progress

Independent Chairman of the Board recently sold US$443k worth of stock

Independent Director Xiaoming Gao has left the company